Abstract
Get full access to this article
View all access options for this article.
References
1.Danaher Corp . and Innovative Genomics Institute. Danaher, Jennifer Doudna, and Innovative Genomics Institute Launch Danaher-IGI Beacon for CRISPR Cures with Aim to Address Hundreds of Diseases Using Gene-editing Platform Solution . 2024 . Available from: https://investors.danaher.com/2024-01-09-Danaher,-Jennifer-Doudna,-and-Innovative-Genomics-Institute-Launch-Danaher-IGI-Beacon-for-CRISPR-Cures-with-Aim-to-Address-Hundreds-of-Diseases-Using-Gene-editing-Platform-Solution [Last accessed:
January 13 , 2024
].
2.Voyager Therapeutics . Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies . 2024 . Available from: https://ir.voyagertherapeutics.com/news-releases/news-release-details/voyager-therapeutics-enters-capsid-license-agreement-and [Last accessed:
January 13 , 2024
].
3.
Marks
P
. Expediting the Development of Cell and Gene Therapy. Alliance for Regenerative Medicine, Cell & Gene State of the Industry Briefing . 2024 . Available from: https://alliancerm.org/arm-event/sotibriefing/ [Last accessed:
January 13 , 2024
].
4.
Eglovitch
J
. FDA eyes collaborative review pilot for gene therapies. Regulatory Focus, A RAPS Publication . 2024 . Available from: https://www.raps.org/news-and-articles/news-articles/2024/1/fda-eyes-collaborative-review-pilot-for-gene-thera [Last accessed:
January 13 , 2024
].
5.Sarepta Therapeutics . Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue . 2024 . Available from: https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-reports-preliminary-fourth-quarter-and-0?_ga=2.261732173.1915995945.1705171018-1725081929.1705171018 [Last accessed:
January 13 , 2024
].
6.
Philippidis
A
. JPM: Prime Medicine Eyes 2024 IND for First Prime Editing Therapy. Genetic Engineering & Biotechnology News . 2024 . Available from: https://www.genengnews.com/topics/genome-editing/jpm-prime-medicine-eyes-2024-ind-for-first-prime-editing-therapy/ [Last accessed:
January 15 , 2024
].
7.4D Molecular Therapeutics and Arbor Biotechnologies, 4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases . 2024 . Available from: https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4dmt-and-arbor-biotechnologies-establish-partnership-co-develop [Last accessed: January 13, 2024].